NDDS in Cancer Therapy: Global Strategic Business Report

Global NDDS in Cancer Therapy Market to Reach $65.4 Billion by 2030

The global market for NDDS in Cancer Therapy estimated at US$14.4 Billion in the year 2022, is projected to reach a revised size of US$65.4 Billion by 2030, growing at a CAGR of 20.9% over the analysis period 2022-2030. Nanoparticles, one of the segments analyzed in the report, is projected to record 20.8% CAGR and reach US$60.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Embolization Particles segment is readjusted to a revised 22.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $4.3 Billion, While China is Forecast to Grow at 19.8% CAGR

The NDDS in Cancer Therapy market in the U.S. is estimated at US$4.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$10.9 Billion by the year 2030 trailing a CAGR of 19.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 18.7% and 17.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 14.5% CAGR.

Select Competitors (Total 46 Featured) -

• 20Med Therapeutics
• Acuitas Therapeutics
• AD Particles
• Ademtech SA
• Advanced NanoTechnology Lab
• Advanced NanoTherapies Inc.
• ADVANO
• Alpha-O Peptides AG
• Applied Nanoparticles
• Avidea Technologies

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and the publisher's Research Platform
• Complimentary updates for one year